There are currently 47 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Prostate Adenocarcinoma participants are Illinois, California, Pennsylvania and Wisconsin.
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT04465500
Recruiting
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, and overall survival for patients receiving this treatment.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT04777071
Recruiting
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Register for Updates
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Recruiting
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen [PSA] after surgical removal of the pros... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +292 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT03821246
Recruiting
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenv... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
NCT06235099
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Tower Urology, Los Angeles, California +10 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Tower Urology, Los Angeles, California +8 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
NCT06369610
Recruiting
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
NCT05027477
Recruiting
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.
Gender:
Male
Ages:
Between 40 years and 80 years
Trial Updated:
04/08/2024
Locations: East Valley Urological Center, Mesa, Arizona +16 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT05726292
Recruiting
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +132 locations
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
NCT04300855
Recruiting
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 405 mgs vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate managed on active surveillance
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates